Hematology CME

  • FREE

    ScientiaCME Transthyretin-mediated amyloidosis (ATTR): successful identification and its role in optimizing outcomes

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Transthyretin-mediated amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. The role of the TTR protein is to transport thyroxine and retinol-binding proteins, and it is vital for cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations, which may account for wild-type ATTR (wtATTR), while a hereditary form of ATTR (hATTR) may be passed to offspring through autosomal dominant inheritance. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.

    Target Audience:
    The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 15, 2023
    • Expiration of CME credit: December 15, 2025
  • FREE

    ScientiaCME Acute hepatic porphyria: optimizing pharmacotherapeutic management strategies

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Acute hepatic porphyria (AHP) is an umbrella term for four types of acute porphyria, the most severe of which is acute intermittent porphyria (AIP). An estimated 80% of AHP cases are AIP, which is an inherited autosomal dominant condition that results from mutations of the third enzyme of heme synthesis, porphobilinogen deaminase. In the Western countries, it is estimated that approximately 1 in 2000 individuals are carriers of the relevant mutated genotype, although the majority have latent AIP and are clinically asymptomatic. Acute attacks occur in less than 10% of the at-risk population, reflecting the role of environmental factors, such as alcohol use, infections, and hormonal changes, among others. AHP symptoms are believed to be caused by ALAS1-mediated accumulation of ALA and PBG in the liver and bloodstream, leading to neurotoxicity.

    Target Audience:
    The following HCPs: hematologists and gastroenterologists; physician assistants, nurse practitioners, and pharmacists who practice in any of the aforementioned areas of specialties; and any other healthcare professionals with an interest in or who clinically encounter patients with AHP.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 06, 2023
    • Expiration of CME credit: July 06, 2025
  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (CTTP): Updates from the American Society of Hematology (ASH) 2019 annual meeting

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    In recent years molecular mechanisms contributing to TTP have been identified: patients diagnosed with TTP have larger von Willebrand factor molecules (vWF) and a defective protease enzyme of A Disintegrinlike And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13), which cleaves larger vWF molecules and inhibits platelet adhesion. In congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome), the gene that codes of ADAMTS13 is defective and cannot properly produce the enzyme, whereas in acquired TTP, antibody production leads to downstream enzymatic deactivation.

    Target Audience:
    The following healthcare professionals: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the ASH 2019 annual meeting relating to congenital TTP
    • Recall the pathophysiology of congenital TTP
    • Describe the clinical manifestations and methods of establishing a diagnosis of cTTP, and apply that information to a patient case
    • List treatment strategies for cTTP, and apply that information to a patient case
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 08/30/2020
    • Expiration of CME credit: 08/30/2022
  • FREE

    ScientiaCME Advances in the management of acute lymphoblastic leukemia (ALL) in children and adolescents

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Acute lymphoblastic leukemia (ALL) is one of a group of malignancies marked by unregulated growth of immature lymphoid cells. Each year, over 6,500 new cases are diagnosed, and ALL claims an estimated 1,390 lives in the same timeframe. The incidence of ALL peaks at 1 to 4 years of age, and it accounts for three quarters of cases of acute leukemia in children. The signs and symptoms of ALL are nonspecific and can include fatigue, malaise, or palpitations associated with anemia; fever with or without infection due to leukopenia or leukocytosis; petechiae; and bleeding or bruising of the oral mucosa or skin. Although the precise etiology of ALL remains unknown, some cases have been associated with exposure to ionizing, toxic chemicals, and herbicides; genetic conditions such as Down syndrome, Fanconi syndrome, neurofibromatosis; and viruses like human T-lymphotropic viruses 1 and 2 and Epstein-Barr virus.

    Target Audience:
    HCPs including: pediatric hematology-oncology, hematology, oncology, pathology, and those who otherwise commonly care for or clinically encounter patients with ALL.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 23, 2023
    • Expiration of CME credit: September 23, 2024
  • FREE

    ScientiaCME Advanced systemic mastocytosis: from recognition to treatment

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

    Target Audience:
    HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 28, 2023
    • Expiration of CME credit: September 28, 2025
  • FREE

    CA: A Cancer Journal for Clinicians

    Some recent topics include:
    • Cancer Screening in the United States, 2013
    • Risk Factors, Pathophysiology, and Treatment of Hot Flashes in Cancer
    • American Cancer Society Lung Cancer Screening Guidelines
    • The Role of Human Papillomavirus in Nongenital Cancers
    • Hypnosis for Cancer Care: Over 200 Years Young
    • The Current Status of Robotic Oncologic Surgery
    • Oral Complications of Cancer and Cancer Therapy: From Cancer Treatment to Survivorship
    • Electronic Patient-Reported Outcome Systems in Oncology Clinical Practice
    • Nutrition and Physical Activity Guidelines for Cancer Survivors

    Target Audience: Oncologists

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1 per course
    • CME credits awarded by: Wiley Health Learning
    • Format: On-Demand Online
  • FREE

    Cleveland Clinic Hematology/Oncology

    There is currently one webcast that offers CME credits:
    Online Webcast – Transanal Colo-Rectal Endoscopic Surgery (TACRES) Ta TME in Rectal Cancer by Cecil Approach

    Target Audience: Physicians specializing in Hematology/Oncology.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: Cleveland Clinic
    • Format: On-Demand Online
    • Material last updated: April 29, 2016
    • Expiration of CME credit: April 29, 2018
  • FREE

    Clinical Care Options Oncology

    About 40 text-based or case-based-interactive activities concerned with aspects of cancer.

    All of these categories offer CME credit: Conference Coverage, Journal Options, Management Series, Treatment Updates, Annual Updates and Interactive Cases.

    Not all activities offer CME; look for the term, “CME-certified”.

    Target Audience: Oncologists

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies depending on course
    • CME credits awarded by: Various Sponsors
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FREE

    CME Zone

    CME Zone offers various courses in many specialties offering CME Credits. The courses are quick and easy to complete.

    Target Audiences: General Surgeons, Oncologists, Various Specialties

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies depending on course
    • CME credits awarded by: Various Sponsors
    • Format: On-Demand Online
  • FREE

    Imedex eLearning Center

    Only the webcasts offer CME credit. Of these, 13 are in Oncology; other areas are Hematology (7) and Gastroenterology (6). Many of the webcasts offer multiple modules.

    Target Audiences:
    Physicians specializing in Hematology, Oncology, or Gastroenterology.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 131
    • CME credits awarded by: Imedex, Inc.
    • Format: On-Demand Online, Online Video, Online Audio